Massachusetts - based software developer Sarepta ##nt has acquired private biotech Myonexus Therapeutics for $ 165 m , after the publication of preliminary early data on a gene therapy clinical trial . it is testing the use of insulin in patients with beta - sarcoglycanopathy , a severe form of limb - girdle muscular disease ( LGMD ) . Early results from three patients demonstrated MYO-101 prompted an average increase of 51 % in beta - sarcoglycan , a protein needed for muscle function , which LGMD patients lack .
Massachusetts-based drug developer Sarepta Therapeutics has acquired private biotech Myonexus Therapeutics for $165m, after the publication of promising early data on a gene therapy clinical trial. Myonexus is testing the use of MYO-101 in patients with beta-sarcoglycanopathy, a severe form of limb-girdle muscular dystrophy (LGMD). Early results from three patients demonstrated MYO-101 prompted an average increase of 51% in beta-sarcoglycan, a protein needed for muscle function, which LGMD sufferers lack.